Current Issue
Application of Quality Risk Management to Process Validation
Robert Dream, Managing Director, HDR Company LLC
A Holistic Phase Appropriate Strategy for HCP-Limits and HCP Characterization
Dr. Markus Haindl, Global Head Gene Therapy Technical Research & Development, Roche Di...
Strategies for Extractable and Leachable Risk Assessment of Polymeric Single Use Systems U...
Ping Wang, Director, Johnson & Johnson
Use of Non-Contact Raman Spectroscopy to Derive Reaction Kinetics
Richard Hart, Senior Director – Head of Automation and Data Science (Previously Asso...
Amsphere A3
JSR Life Sciences
Featured Articles
Comparison of purification performance of Amsphere A3 to other commercially available Protein A resins
Amsphere A3 – protein A resin: an optimized media to minimize the impact of elution buffer selection
Scheduling and Optimization of Biomanufacturing Activities in Multi-product Facilities with Disposable Technologies
Gloria Gadea-Lopez, Ph.D. is Director of Production and Business Systems at the Shire Lexington, John Maguireis the Associate Director of Manufacturing Systems at Shire’s Lexington and Megan Rabideau is a Manufacturing Systems Engineer at Shire’s Lexington
Successful Wetting for Filter Integrity Testing in Volume-Restricted Systems
View All Featured ArticlesHeadline News
Pasritamig combination delivers 73% PSA response rate in advanced prostate cancer Phase I study
Regeneron CIDEBsiRNA delivers up to 80% liver fat reduction in early MASLD study
CAPLYTA shows rapid improvement in bipolar mania in second pivotal Phase III study
Read All Headlines
Upcoming Webinars
View All Upcoming WebinarsPast Webinars
Points To Consider: Demonstrating Comparability Between Recombinant and Lysate Reagent For BET Testing
Presented by Karen Zink McCullough, Owner, Principal Consultant at MMI Associates, Nicola Reid, Associate Director Product Management, Endotoxin Products at Charles River Laboratories and Veronika Wills, Manager, Technical Services At Associates of Cape Cod, Inc
09th September 2021
CCAB: Addressing the risk of microbial impurities in Biologics and certain Advanced Therapy Medicinal Products (ATMPs)
Presented by Dr Friedrich von Wintzingerode, QC Lead iNeST (individual Neoepitope Specific Therapy), Roche and Nahuel Paolini, PhD, Sanquin Reagents
28th March 2022
Data as an asset – what does this mean to you?
Presented by Christos Varsakelis, Team Lead Artificial Intelligence/Machine Learning at The Janssen Pharmaceutical Companies of Johnson & Johnson and Klaus Mauch, CEO at Yokogawa Insilico Biotechnology GmbH
12th April 2022
View All Past Webinars
Featured Companies
View All Companies
Featured Video
At Pall we help you select the process model that’s perfect for you. Ensuring it’s adapted to meet your precise needs and assembled flawlessly, ready for the future, from day one.
View All Videos
Technical Papers
Caustic Stability of Amsphere A3 : Cycling Study with 0.5 M NaOH
Amsphere A3 – protein A resin: an optimized media to minimize the impact of elution buffer selection
From Compliance to Circularity: Three Ways Pharma Manufacturers Can Rethink Resource Management
Read All Technical Papers
Featured Products
Decrease Cleaning Validation Time and Resources
AdvantaPure
Amsphere™ A3 Protein A Resin – JSR Life Sciences
View All Products
